Cargando…

Anticancer efficacy of 3-(4-isopropyl) benzylidene-8-ethoxy, 6-methyl, chroman-4-one (SBL-060), a novel, dual, estrogen receptor-Akt kinase inhibitor in acute myeloid leukemia cells

Estrogen receptor (ER) α is expressed in a subset of patient-derived acute myeloid leukemia (AML) cells, whereas Akt is predominantly expressed in most types of AML. Targeting AML with dual inhibitors is a novel approach to combat the disease. Herein, we examined a novel small molecule, 3-(4-isoprop...

Descripción completa

Detalles Bibliográficos
Autores principales: SHAHRANI, MESFER AL, RAJAGOPALAN, PRASANNA, ABOHASSAN, MOHAMMAD, ALSHAHRANI, MOHAMMAD, ALRAEY, YASSER, GAHTANI, REEM M., RADHAKRISHNAN, SURESH, DAGREERY, KHLOOD
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tech Science Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207952/
https://www.ncbi.nlm.nih.gov/pubmed/37304671
http://dx.doi.org/10.32604/or.2022.03539
_version_ 1785046565090492416
author SHAHRANI, MESFER AL
RAJAGOPALAN, PRASANNA
ABOHASSAN, MOHAMMAD
ALSHAHRANI, MOHAMMAD
ALRAEY, YASSER
GAHTANI, REEM M.
RADHAKRISHNAN, SURESH
DAGREERY, KHLOOD
author_facet SHAHRANI, MESFER AL
RAJAGOPALAN, PRASANNA
ABOHASSAN, MOHAMMAD
ALSHAHRANI, MOHAMMAD
ALRAEY, YASSER
GAHTANI, REEM M.
RADHAKRISHNAN, SURESH
DAGREERY, KHLOOD
author_sort SHAHRANI, MESFER AL
collection PubMed
description Estrogen receptor (ER) α is expressed in a subset of patient-derived acute myeloid leukemia (AML) cells, whereas Akt is predominantly expressed in most types of AML. Targeting AML with dual inhibitors is a novel approach to combat the disease. Herein, we examined a novel small molecule, 3-(4-isopropyl) benzylidene-8-ethoxy,6-methyl, chroman-4-one (SBL-060), capable of targeting AML cells by inhibiting ERα and Akt kinase. The chemical properties of SBL-060 were identified by proton nuclear magnetic resonance ((1)H-NMR), (13)C-NMR, and mass spectroscopy. In silico docking was performed using an automated protocol with AutoDock-VINA. THP-1 and HL-60 cell lines were differentiated using phorbol 12-myristate 13-acetate. ERα inhibition was assessed using ELISA. The MTT assay assessed cell viability. Flow cytometry was performed for cell cycle, apoptosis, and p-Akt analyses. Chemical analysis identified the compound as 3-(4-isopropyl) benzylidene-8-ethoxy,6-methyl, chroman-4-one, which showed high binding efficacy toward ER, with a ΔG(binding) score of −7.4 kcal/mol. SBL-060 inhibited ERα, exhibiting IC(50) values of 448 and 374.3 nM in THP-1 and HL-60 cells, respectively. Regarding inhibited cell proliferation, GI(50) values of SBL-060 were 244.1 and 189.9 nM for THP-1 and HL-60 cells, respectively. In addition, a dose-dependent increase in sub G(0)/G(1) phase cell cycle arrest and total apoptosis was observed after treatment with SBL-060 in both cell types. SBL-060 also dose-dependently increased the p-Akt-positive populations in both THP-1 and HL-60 cells. Our results indicate that SBL-060 has excellent efficacy against differentiated AML cell types by inhibiting ER and Akt kinase, warranting further preclinical evaluations.
format Online
Article
Text
id pubmed-10207952
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Tech Science Press
record_format MEDLINE/PubMed
spelling pubmed-102079522023-06-10 Anticancer efficacy of 3-(4-isopropyl) benzylidene-8-ethoxy, 6-methyl, chroman-4-one (SBL-060), a novel, dual, estrogen receptor-Akt kinase inhibitor in acute myeloid leukemia cells SHAHRANI, MESFER AL RAJAGOPALAN, PRASANNA ABOHASSAN, MOHAMMAD ALSHAHRANI, MOHAMMAD ALRAEY, YASSER GAHTANI, REEM M. RADHAKRISHNAN, SURESH DAGREERY, KHLOOD Oncol Res Article Estrogen receptor (ER) α is expressed in a subset of patient-derived acute myeloid leukemia (AML) cells, whereas Akt is predominantly expressed in most types of AML. Targeting AML with dual inhibitors is a novel approach to combat the disease. Herein, we examined a novel small molecule, 3-(4-isopropyl) benzylidene-8-ethoxy,6-methyl, chroman-4-one (SBL-060), capable of targeting AML cells by inhibiting ERα and Akt kinase. The chemical properties of SBL-060 were identified by proton nuclear magnetic resonance ((1)H-NMR), (13)C-NMR, and mass spectroscopy. In silico docking was performed using an automated protocol with AutoDock-VINA. THP-1 and HL-60 cell lines were differentiated using phorbol 12-myristate 13-acetate. ERα inhibition was assessed using ELISA. The MTT assay assessed cell viability. Flow cytometry was performed for cell cycle, apoptosis, and p-Akt analyses. Chemical analysis identified the compound as 3-(4-isopropyl) benzylidene-8-ethoxy,6-methyl, chroman-4-one, which showed high binding efficacy toward ER, with a ΔG(binding) score of −7.4 kcal/mol. SBL-060 inhibited ERα, exhibiting IC(50) values of 448 and 374.3 nM in THP-1 and HL-60 cells, respectively. Regarding inhibited cell proliferation, GI(50) values of SBL-060 were 244.1 and 189.9 nM for THP-1 and HL-60 cells, respectively. In addition, a dose-dependent increase in sub G(0)/G(1) phase cell cycle arrest and total apoptosis was observed after treatment with SBL-060 in both cell types. SBL-060 also dose-dependently increased the p-Akt-positive populations in both THP-1 and HL-60 cells. Our results indicate that SBL-060 has excellent efficacy against differentiated AML cell types by inhibiting ER and Akt kinase, warranting further preclinical evaluations. Tech Science Press 2022-08-01 /pmc/articles/PMC10207952/ /pubmed/37304671 http://dx.doi.org/10.32604/or.2022.03539 Text en © 2021 Shahrani et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
SHAHRANI, MESFER AL
RAJAGOPALAN, PRASANNA
ABOHASSAN, MOHAMMAD
ALSHAHRANI, MOHAMMAD
ALRAEY, YASSER
GAHTANI, REEM M.
RADHAKRISHNAN, SURESH
DAGREERY, KHLOOD
Anticancer efficacy of 3-(4-isopropyl) benzylidene-8-ethoxy, 6-methyl, chroman-4-one (SBL-060), a novel, dual, estrogen receptor-Akt kinase inhibitor in acute myeloid leukemia cells
title Anticancer efficacy of 3-(4-isopropyl) benzylidene-8-ethoxy, 6-methyl, chroman-4-one (SBL-060), a novel, dual, estrogen receptor-Akt kinase inhibitor in acute myeloid leukemia cells
title_full Anticancer efficacy of 3-(4-isopropyl) benzylidene-8-ethoxy, 6-methyl, chroman-4-one (SBL-060), a novel, dual, estrogen receptor-Akt kinase inhibitor in acute myeloid leukemia cells
title_fullStr Anticancer efficacy of 3-(4-isopropyl) benzylidene-8-ethoxy, 6-methyl, chroman-4-one (SBL-060), a novel, dual, estrogen receptor-Akt kinase inhibitor in acute myeloid leukemia cells
title_full_unstemmed Anticancer efficacy of 3-(4-isopropyl) benzylidene-8-ethoxy, 6-methyl, chroman-4-one (SBL-060), a novel, dual, estrogen receptor-Akt kinase inhibitor in acute myeloid leukemia cells
title_short Anticancer efficacy of 3-(4-isopropyl) benzylidene-8-ethoxy, 6-methyl, chroman-4-one (SBL-060), a novel, dual, estrogen receptor-Akt kinase inhibitor in acute myeloid leukemia cells
title_sort anticancer efficacy of 3-(4-isopropyl) benzylidene-8-ethoxy, 6-methyl, chroman-4-one (sbl-060), a novel, dual, estrogen receptor-akt kinase inhibitor in acute myeloid leukemia cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207952/
https://www.ncbi.nlm.nih.gov/pubmed/37304671
http://dx.doi.org/10.32604/or.2022.03539
work_keys_str_mv AT shahranimesferal anticancerefficacyof34isopropylbenzylidene8ethoxy6methylchroman4onesbl060anoveldualestrogenreceptoraktkinaseinhibitorinacutemyeloidleukemiacells
AT rajagopalanprasanna anticancerefficacyof34isopropylbenzylidene8ethoxy6methylchroman4onesbl060anoveldualestrogenreceptoraktkinaseinhibitorinacutemyeloidleukemiacells
AT abohassanmohammad anticancerefficacyof34isopropylbenzylidene8ethoxy6methylchroman4onesbl060anoveldualestrogenreceptoraktkinaseinhibitorinacutemyeloidleukemiacells
AT alshahranimohammad anticancerefficacyof34isopropylbenzylidene8ethoxy6methylchroman4onesbl060anoveldualestrogenreceptoraktkinaseinhibitorinacutemyeloidleukemiacells
AT alraeyyasser anticancerefficacyof34isopropylbenzylidene8ethoxy6methylchroman4onesbl060anoveldualestrogenreceptoraktkinaseinhibitorinacutemyeloidleukemiacells
AT gahtanireemm anticancerefficacyof34isopropylbenzylidene8ethoxy6methylchroman4onesbl060anoveldualestrogenreceptoraktkinaseinhibitorinacutemyeloidleukemiacells
AT radhakrishnansuresh anticancerefficacyof34isopropylbenzylidene8ethoxy6methylchroman4onesbl060anoveldualestrogenreceptoraktkinaseinhibitorinacutemyeloidleukemiacells
AT dagreerykhlood anticancerefficacyof34isopropylbenzylidene8ethoxy6methylchroman4onesbl060anoveldualestrogenreceptoraktkinaseinhibitorinacutemyeloidleukemiacells